First Trust Nasdaq Pharmaceuticals ETF (FTXH) Valuation
FTXH valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 39.2 trailing earnings
- Forward P/E
- 14.7 analyst estimates
- Price / sales
- 4.73
- Price / book
- 4.85
- EV / EBITDA
- 14.7
- Earnings yield
- 2.55% inverse of P/E
- Dividend yield
- 1.47% of the holdings
- Return on equity
- 12.4% combined
- Net margin
- 12.1% combined
- Beta
- 0.52 weighted, vs S&P 500
FTXH valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| FTXH | 39.2 | 14.7 | 4.73 | 4.85 | 1.47% | 12.4% | 12.1% | 15.9% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
FTXH valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 98.4% | 39.2 | 14.7 | 4.73 | 4.85 | 1.47% | 12.4% |
FTXH earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How FTXH weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
FTXH largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 7.77% | 42.2 | 24.4 | 14.1 | 0.55% | 7.40% |
| ABBV | AbbVie Inc. | 7.42% | 80.6 | 16.4 | 7.8 | 2.42% | 3.70% |
| PFE | Pfizer Inc. | 7.14% | 38.9 | 9.7 | 2.6 | 5.81% | 7.37% |
| JNJ | Johnson & Johnson | 7.14% | 38.8 | 21.0 | 6.2 | 2.10% | 7.40% |
| MRK | Merck & Co., Inc. | 6.53% | 115.8 | 15.3 | 5.4 | 2.33% | 2.27% |
| BIIB | Biogen Inc. | 4.03% | 41.3 | 13.9 | 3.4 | — | 3.92% |
| VTRS | Viatris Inc. | 3.82% | — | 6.4 | 1.5 | 2.57% | −2.96% |
| ZTS | Zoetis Inc. | 3.62% | 13.1 | 12.0 | 3.4 | 2.67% | 11.15% |
| GILD | Gilead Sciences, Inc. | 3.55% | — | 15.6 | 6.4 | 2.10% | −2.42% |
| UTHR | United Therapeutics Corporation | 3.52% | 19.1 | 16.4 | 7.2 | — | 7.40% |
| AMGN | Amgen Inc. | 3.44% | 26.9 | 16.7 | 6.1 | 2.33% | 5.15% |
| REGN | Regeneron Pharmaceuticals, Inc. | 3.39% | 19.6 | 14.5 | 5.2 | 0.48% | 6.97% |
| VRTX | Vertex Pharmaceuticals Incorporated | 3.35% | 28.9 | 24.1 | 10.1 | — | 4.66% |
| INCY | Incyte Corporation | 3.27% | 14.4 | 14.7 | 3.9 | — | 9.13% |
| BMY | Bristol-Myers Squibb Company | 3.12% | 13.2 | 9.4 | 2.5 | 4.22% | 9.51% |
| EXEL | Exelixis, Inc. | 2.57% | 19.6 | 13.6 | 6.3 | — | 5.27% |
| JAZZ | Jazz Pharmaceuticals plc | 2.44% | 14.4 | 10.9 | 3.0 | — | 6.80% |
| ILMN | Illumina, Inc. | 2.08% | 49.0 | 40.3 | 8.8 | — | 1.71% |
| HALO | Halozyme Therapeutics, Inc. | 1.70% | 35.6 | 11.5 | 8.3 | — | 1.92% |
| MEDP | Medpace Holdings, Inc. | 1.57% | 36.3 | 31.9 | 6.2 | — | 1.74% |
| NBIX | Neurocrine Biosciences, Inc. | 1.19% | 19.9 | 14.1 | 4.1 | — | 2.40% |
| CRL | Charles River Laboratories International, Inc. | 1.18% | — | 22.4 | 3.6 | — | −0.76% |
| ALNY | Alnylam Pharmaceuticals, Inc. | 1.12% | 39.1 | 19.7 | 6.5 | — | 1.15% |
| ELAN | Elanco Animal Health Incorporated | 1.12% | — | 17.4 | 2.3 | — | −0.78% |
| BMRN | BioMarin Pharmaceutical Inc. | 1.08% | 147.8 | 9.4 | 3.1 | — | 0.30% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About FTXH valuation
Adding up its 47 holdings with company data, FTXH trades at 39.2 times trailing earnings and 14.7 times analysts' forward estimates, with a price-to-book ratio of 4.85 and a dividend yield of 1.47%. Its earnings yield of 2.55% is 2.78 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 54.5% of the fund and earn 45.2% of its combined profit. Companies that lost money over the past year are 15.9% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 98.7% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: FTXH chart, FTXH performance, FTXH holdings, FTXH dividends.
FTXH valuation FAQ
What is the P/E ratio of FTXH?
Based on its holdings, FTXH has a trailing P/E of 39.2 and a forward P/E of 14.7 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of FTXH?
The trailing earnings yield is 2.55% (1 ÷ P/E) and the forward earnings yield 6.79%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is FTXH more expensive than the S&P 500?
FTXH trades at 39.2 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 14.7 and 19.9.
What is the price-to-book ratio of FTXH?
The holdings of FTXH trade at 4.85 times book value, with a combined return on equity of 12.4%.